Perspectives for therapy of treatment‐resistant depression
A high proportion of depressed patients fail to respond to antidepressant drug treatment. Treatment‐resistant depression (TRD) is a major challenge for the psychopharmacology of mood disorders. Only in the past decade have novel treatments, including deep brain stimulation (DBS) and ketamine, been d...
Gespeichert in:
| Veröffentlicht in: | British journal of pharmacology 2022-09, Vol.179 (17), p.4181-4200 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4200 |
|---|---|
| container_issue | 17 |
| container_start_page | 4181 |
| container_title | British journal of pharmacology |
| container_volume | 179 |
| creator | Papp, Mariusz Cubala, Wiesław Jerzy Swiecicki, Lukasz Newman‐Tancredi, Adrian Willner, Paul |
| description | A high proportion of depressed patients fail to respond to antidepressant drug treatment. Treatment‐resistant depression (TRD) is a major challenge for the psychopharmacology of mood disorders. Only in the past decade have novel treatments, including deep brain stimulation (DBS) and ketamine, been discovered that provide rapid and sometimes prolonged relief to a high proportion of TRD sufferers. In this review, we consider the current status of TRD from four perspectives: the challenge of developing an appropriate regulatory framework for novel rapidly acting antidepressants; the efficacy of non‐pharmacological somatic therapies; the development of an animal model of TRD and its use to understand the neural basis of antidepressant non‐response; and the potential for rapid antidepressant action from targets (such as 5‐HT1A receptors) beyond the glutamate receptor.
LINKED ARTICLES
This article is part of a themed issue on New discoveries and perspectives in mental and pain disorders. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.17/issuetoc |
| doi_str_mv | 10.1111/bph.15596 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2541319907</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2541319907</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4716-56a329477f597617c8b63f129ff8d1c4de10741a2105cebff7c08aa2fe6f487f3</originalsourceid><addsrcrecordid>eNp1kM1KAzEQgIMoWKsH32DBix62zWSzm13wokWtULAHPYc0ndAt282apJbefASf0Scxup4E5zIM880PHyHnQEcQY7zoViPI86o4IAPgokjzrIRDMqCUihSgLI_JifdrSmNT5ANyPUfnO9ShfkOfGOuSsEKnun1iTRIcqrDBNny-fzj0tQ-qDckSu1j42ran5MioxuPZbx6Sl_u758k0nT09PE5uZqnmAuILhcpYFe-ZvBIFCF0uiswAq4wpl6D5EoEKDooBzTUujBGalkoxg4XhpTDZkFz2eztnX7fog9zUXmPTqBbt1kuWc8igqqiI6MUfdG23ro3fSSYo4yw6gUhd9ZR21nuHRnau3ii3l0Dlt0cZPcofj5Ed9-yubnD_Pyhv59N-4gtE_nSo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2702424761</pqid></control><display><type>article</type><title>Perspectives for therapy of treatment‐resistant depression</title><source>Wiley Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>Alma/SFX Local Collection</source><creator>Papp, Mariusz ; Cubala, Wiesław Jerzy ; Swiecicki, Lukasz ; Newman‐Tancredi, Adrian ; Willner, Paul</creator><creatorcontrib>Papp, Mariusz ; Cubala, Wiesław Jerzy ; Swiecicki, Lukasz ; Newman‐Tancredi, Adrian ; Willner, Paul</creatorcontrib><description>A high proportion of depressed patients fail to respond to antidepressant drug treatment. Treatment‐resistant depression (TRD) is a major challenge for the psychopharmacology of mood disorders. Only in the past decade have novel treatments, including deep brain stimulation (DBS) and ketamine, been discovered that provide rapid and sometimes prolonged relief to a high proportion of TRD sufferers. In this review, we consider the current status of TRD from four perspectives: the challenge of developing an appropriate regulatory framework for novel rapidly acting antidepressants; the efficacy of non‐pharmacological somatic therapies; the development of an animal model of TRD and its use to understand the neural basis of antidepressant non‐response; and the potential for rapid antidepressant action from targets (such as 5‐HT1A receptors) beyond the glutamate receptor.
LINKED ARTICLES
This article is part of a themed issue on New discoveries and perspectives in mental and pain disorders. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.17/issuetoc</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.15596</identifier><language>eng</language><publisher>London: Blackwell Publishing Ltd</publisher><subject>5‐HT1A receptors ; Animal models ; Antidepressants ; Deep brain stimulation ; Glutamic acid receptors ; Ketamine ; Mental depression ; regulatory challenges ; somatic therapies ; treatment‐resistant depression</subject><ispartof>British journal of pharmacology, 2022-09, Vol.179 (17), p.4181-4200</ispartof><rights>2021 The British Pharmacological Society</rights><rights>2022 The British Pharmacological Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4716-56a329477f597617c8b63f129ff8d1c4de10741a2105cebff7c08aa2fe6f487f3</citedby><cites>FETCH-LOGICAL-c4716-56a329477f597617c8b63f129ff8d1c4de10741a2105cebff7c08aa2fe6f487f3</cites><orcidid>0000-0002-2923-5714 ; 0000-0001-6343-8454 ; 0000-0003-1282-3939</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbph.15596$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbph.15596$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids></links><search><creatorcontrib>Papp, Mariusz</creatorcontrib><creatorcontrib>Cubala, Wiesław Jerzy</creatorcontrib><creatorcontrib>Swiecicki, Lukasz</creatorcontrib><creatorcontrib>Newman‐Tancredi, Adrian</creatorcontrib><creatorcontrib>Willner, Paul</creatorcontrib><title>Perspectives for therapy of treatment‐resistant depression</title><title>British journal of pharmacology</title><description>A high proportion of depressed patients fail to respond to antidepressant drug treatment. Treatment‐resistant depression (TRD) is a major challenge for the psychopharmacology of mood disorders. Only in the past decade have novel treatments, including deep brain stimulation (DBS) and ketamine, been discovered that provide rapid and sometimes prolonged relief to a high proportion of TRD sufferers. In this review, we consider the current status of TRD from four perspectives: the challenge of developing an appropriate regulatory framework for novel rapidly acting antidepressants; the efficacy of non‐pharmacological somatic therapies; the development of an animal model of TRD and its use to understand the neural basis of antidepressant non‐response; and the potential for rapid antidepressant action from targets (such as 5‐HT1A receptors) beyond the glutamate receptor.
LINKED ARTICLES
This article is part of a themed issue on New discoveries and perspectives in mental and pain disorders. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.17/issuetoc</description><subject>5‐HT1A receptors</subject><subject>Animal models</subject><subject>Antidepressants</subject><subject>Deep brain stimulation</subject><subject>Glutamic acid receptors</subject><subject>Ketamine</subject><subject>Mental depression</subject><subject>regulatory challenges</subject><subject>somatic therapies</subject><subject>treatment‐resistant depression</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kM1KAzEQgIMoWKsH32DBix62zWSzm13wokWtULAHPYc0ndAt282apJbefASf0Scxup4E5zIM880PHyHnQEcQY7zoViPI86o4IAPgokjzrIRDMqCUihSgLI_JifdrSmNT5ANyPUfnO9ShfkOfGOuSsEKnun1iTRIcqrDBNny-fzj0tQ-qDckSu1j42ran5MioxuPZbx6Sl_u758k0nT09PE5uZqnmAuILhcpYFe-ZvBIFCF0uiswAq4wpl6D5EoEKDooBzTUujBGalkoxg4XhpTDZkFz2eztnX7fog9zUXmPTqBbt1kuWc8igqqiI6MUfdG23ro3fSSYo4yw6gUhd9ZR21nuHRnau3ii3l0Dlt0cZPcofj5Ed9-yubnD_Pyhv59N-4gtE_nSo</recordid><startdate>202209</startdate><enddate>202209</enddate><creator>Papp, Mariusz</creator><creator>Cubala, Wiesław Jerzy</creator><creator>Swiecicki, Lukasz</creator><creator>Newman‐Tancredi, Adrian</creator><creator>Willner, Paul</creator><general>Blackwell Publishing Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2923-5714</orcidid><orcidid>https://orcid.org/0000-0001-6343-8454</orcidid><orcidid>https://orcid.org/0000-0003-1282-3939</orcidid></search><sort><creationdate>202209</creationdate><title>Perspectives for therapy of treatment‐resistant depression</title><author>Papp, Mariusz ; Cubala, Wiesław Jerzy ; Swiecicki, Lukasz ; Newman‐Tancredi, Adrian ; Willner, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4716-56a329477f597617c8b63f129ff8d1c4de10741a2105cebff7c08aa2fe6f487f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>5‐HT1A receptors</topic><topic>Animal models</topic><topic>Antidepressants</topic><topic>Deep brain stimulation</topic><topic>Glutamic acid receptors</topic><topic>Ketamine</topic><topic>Mental depression</topic><topic>regulatory challenges</topic><topic>somatic therapies</topic><topic>treatment‐resistant depression</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Papp, Mariusz</creatorcontrib><creatorcontrib>Cubala, Wiesław Jerzy</creatorcontrib><creatorcontrib>Swiecicki, Lukasz</creatorcontrib><creatorcontrib>Newman‐Tancredi, Adrian</creatorcontrib><creatorcontrib>Willner, Paul</creatorcontrib><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Papp, Mariusz</au><au>Cubala, Wiesław Jerzy</au><au>Swiecicki, Lukasz</au><au>Newman‐Tancredi, Adrian</au><au>Willner, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Perspectives for therapy of treatment‐resistant depression</atitle><jtitle>British journal of pharmacology</jtitle><date>2022-09</date><risdate>2022</risdate><volume>179</volume><issue>17</issue><spage>4181</spage><epage>4200</epage><pages>4181-4200</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>A high proportion of depressed patients fail to respond to antidepressant drug treatment. Treatment‐resistant depression (TRD) is a major challenge for the psychopharmacology of mood disorders. Only in the past decade have novel treatments, including deep brain stimulation (DBS) and ketamine, been discovered that provide rapid and sometimes prolonged relief to a high proportion of TRD sufferers. In this review, we consider the current status of TRD from four perspectives: the challenge of developing an appropriate regulatory framework for novel rapidly acting antidepressants; the efficacy of non‐pharmacological somatic therapies; the development of an animal model of TRD and its use to understand the neural basis of antidepressant non‐response; and the potential for rapid antidepressant action from targets (such as 5‐HT1A receptors) beyond the glutamate receptor.
LINKED ARTICLES
This article is part of a themed issue on New discoveries and perspectives in mental and pain disorders. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.17/issuetoc</abstract><cop>London</cop><pub>Blackwell Publishing Ltd</pub><doi>10.1111/bph.15596</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0002-2923-5714</orcidid><orcidid>https://orcid.org/0000-0001-6343-8454</orcidid><orcidid>https://orcid.org/0000-0003-1282-3939</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1188 |
| ispartof | British journal of pharmacology, 2022-09, Vol.179 (17), p.4181-4200 |
| issn | 0007-1188 1476-5381 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2541319907 |
| source | Wiley Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; Alma/SFX Local Collection |
| subjects | 5‐HT1A receptors Animal models Antidepressants Deep brain stimulation Glutamic acid receptors Ketamine Mental depression regulatory challenges somatic therapies treatment‐resistant depression |
| title | Perspectives for therapy of treatment‐resistant depression |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T13%3A22%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Perspectives%20for%20therapy%20of%20treatment%E2%80%90resistant%20depression&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Papp,%20Mariusz&rft.date=2022-09&rft.volume=179&rft.issue=17&rft.spage=4181&rft.epage=4200&rft.pages=4181-4200&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.15596&rft_dat=%3Cproquest_cross%3E2541319907%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2702424761&rft_id=info:pmid/&rfr_iscdi=true |